2023 World Conference on Lung Cancer (Posters)-EP12.01. Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results

EP12.01. Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results - PDF(Abstract)

Back to course

Pdf Summary

This study presented updated results on the outcomes of patients with metastatic non-small cell lung cancer (NSCLC) who have EGFR co-mutations and were treated with aumolertinib as a first-line therapy. Aumolertinib is a third-generation EGFR tyrosine kinase inhibitor that inhibits EGFR sensitizing and resistance mutations. The primary endpoint of this retrospective study was the objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. <br /><br />Data from 62 advanced NSCLC patients with EGFR co-mutations were collected. Of these patients, 85.5% received aumolertinib monotherapy, while 14.5% received aumolertinib in combination with bevacizumab or pemetrexed. The ORR and DCR in patients receiving aumolertinib monotherapy were 66% and 96.2%, respectively. The median PFS was 20 months. Subgroup analysis showed that patients with different genotypes had varying response rates and PFS durations. <br /><br />In the PD-L1 TPS 1 subgroup, two patients with PD-L1 TPS 80 achieved a partial response, with a percentage change in target lesion size of 75% and 77%, respectively. Aumolertinib combination therapy showed superior antitumor activity, with an ORR of 88.9%, DCR of 100%, and a PFS rate at 24 months of 56.3%. No new safety concerns were identified. <br /><br />In conclusion, both aumolertinib monotherapy and combination therapy showed promising results in patients with EGFR-mutant NSCLC with co-mutations. The study suggests that aumolertinib could be an effective treatment option for this group of patients.

Asset Subtitle

Shencun Fang

Meta Tag

Speaker Shencun Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

metastatic non-small cell lung cancer

NSCLC

EGFR co-mutations

aumolertinib

first-line therapy

retrospective study

objective response rate

disease control rate

progression-free survival

overall survival